| Zhiping Mo, MD | |
|
1610 Orchard Dr, Chambersburg, PA 17201-9206 | |
| (717) 261-0929 | |
| (717) 261-0902 |
| Full Name | Zhiping Mo |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 1610 Orchard Dr, Chambersburg, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720288293 | NPI | - | NPPES |
| 103373378 | Medicaid | PA |
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
In the fight against obesity, bariatric surgery is currently the most effective treatment; however, only 1 to 2 percent of qualified patients receive this surgery due to limited access, patient choice, associated risks and the high costs. A novel treatment method - endoscopic sleeve gastroplasty - might offer a new solution for obese patients.
The United States Food and Drug Administration have issued a warning regarding some substances present in a brand of Ranitidine that could be carcinogenic. In their first warning issued on the 13th of this month, the FDA warns that one of the brands of Ranitidine, Zantac is said to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is a known carcinogen, the report reads based on lab data and is also found in the environment, food and water the report adds.
An advanced type of cancer radiation is more successful than traditional radiation in avoiding "dry mouth" when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.
People trying to talk to Siri may soon no longer have to look like they're about to eat their iPhones, thanks to a new technology demonstration that solves the "Cocktail Party" conundrum.
EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Zhiping Mo, MD 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 261-0929 | Zhiping Mo, MD 1610 Orchard Dr, Chambersburg, PA 17201-9206 Ph: (717) 261-0929 |
News Archive
In the fight against obesity, bariatric surgery is currently the most effective treatment; however, only 1 to 2 percent of qualified patients receive this surgery due to limited access, patient choice, associated risks and the high costs. A novel treatment method - endoscopic sleeve gastroplasty - might offer a new solution for obese patients.
The United States Food and Drug Administration have issued a warning regarding some substances present in a brand of Ranitidine that could be carcinogenic. In their first warning issued on the 13th of this month, the FDA warns that one of the brands of Ranitidine, Zantac is said to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is a known carcinogen, the report reads based on lab data and is also found in the environment, food and water the report adds.
An advanced type of cancer radiation is more successful than traditional radiation in avoiding "dry mouth" when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.
People trying to talk to Siri may soon no longer have to look like they're about to eat their iPhones, thanks to a new technology demonstration that solves the "Cocktail Party" conundrum.
EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.
› Verified 8 days ago
Francine R. Fields, M.D. Preventive Medicine Medicare: Medicare Enrolled Practice Location: 757 Norland Ave, Suite 101, Chambersburg, PA 17201 Phone: 717-217-6760 Fax: 717-217-6912 | |
Dr. Theodore M Sofish, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1610 Orchard Dr, Occupational Health Associates, Chambersburg, PA 17201 Phone: 717-261-0929 Fax: 717-264-4969 | |
Joshua Merris, MD Preventive Medicine Medicare: Medicare Enrolled Practice Location: 1610 Orchard Dr, Chambersburg, PA 17201 Phone: 717-261-0929 Fax: 717-261-0902 |